Publication | Open Access

Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway

InflammationCytokineAutoimmune DiseaseImmune RegulationImmunologyStat3-mediated SuppressionImmunologic MechanismAutoimmunityHumoral ImmunityPd-1/pd-l1 PathwayImmunosuppressionImmunotherapyMedicineCell BiologyCell SignalingRegulatory B-cell Function